The Global Organ Transplantation Market was valued at USD 12.92 Billion in 2022 and is projected to reach USD 27.25 Billion by 2030, registering a CAGR of 9.20% for the forecast period 2023-2030.
The surgical process of transplantation involves taking a living tissue or organ and implanting it in a different body or part of the body. One of the main reasons driving the growth of the transplantation market is the increased demand for these procedures and the introduction of innovative products to stop these procedures from failing. One of the main drivers of the market's expansion is the rising demand for innovative tissue transplantation products and organ transplantation as treatments for organ failure. Many conditions, including severe trauma, blood loss, poisoning, drug abuse, leukemia, sepsis, and other acute illnesses, are typically the cause of organ failure. Worldwide, there is a great need for tissue and organ transplants, primarily for the kidney, heart, liver, and lungs. Among the main causes of organ failure are unhealthy food habits, alcoholism, inactivity, and drug misuse. So, it is anticipated that the demand for transplant products will increase shortly.
- 2022: USD 12.92 Billion
- 2030: USD 27.25 Billion
- CAGR (2023-2030): 9.20%
Organ Transplantation Market Dynamics
Drivers Propelling the Demand for Organ Transplantation include
Increasing the Number of Organ Failure Cases : Severe trauma, poisoning, leukemia, drug abuse, loss of blood, and other acute illnesses are among the factors that can lead to organ failure. Severe organ failure is linked to serious diseases resulting from a decline in organ function. These conditions can be brought on by smoking, alcohol and drug abuse, and obesity, and they can ultimately lead to organ failure. As a result, there is a huge need for tissue and organ transplants worldwide, particularly for the kidney, liver, heart, bone marrow, and lungs. Global organ failure rates are on the rise due to a combination of factors including an increase in acute illnesses and an aging population, which is driving up demand for organ transplant procedures. The lack of donor organs may be addressed in part by new transplant technologies like artificial organs and xenotransplantation, which is the transplantation of animal organs into humans. Compared to traditional transplant procedures, minimally invasive transplant procedures like laparoscopic transplantation are less invasive. Patients may experience fewer problems and quicker recovery periods as a result. The use of organ transplantation as a therapy for end-stage organ failure is growing in acceptance. This is because transplant recipients' quality of life has improved and transplant success rates have been rising. For patients with end-stage organ failure, the market for organ transplants is expanding, which is a good thing, due to this factor fueling the growth of organ transplantation market.
For instance, in January 2023, according to UNOS, In 2022, 42,887 organ transplants were performed in the United States, an increase of 3.7 percent over 2021 and a new annual record, according to preliminary data from United Network for Organ Sharing (UNOS), which serves as the national Organ Procurement and Transplantation Network under federal contract.
Developments in Technology for Organ Transplant Procedures : Organ transplantation methods and procedures have evolved as a result of advanced technologies, which are anticipated to drive market expansion. Market expansion can be attributed to new and improved transplantation products, such as surgical medical instruments, tissue products, and tissue typing technology. Advances in PCR technology, including enhanced system architecture and sophisticated assays, offer tissue typing with exceptional accuracy and efficacy. Furthermore, the acceptance of organ transplantation is being aided by technological developments in the field of 3D bioprinting. The need for 3D bioprinting has grown as a result of the ongoing lack of organ donors and the rise in patients waiting for transplants. These methods are applied in the fabrication of tissue, the creation of customized prosthetics, and the support of transplantation using artificial models. The need for these operations is also being increased by improved organ preservation facilities. When performing transplant surgery, organ preservation is crucial. Procedure results are directly impacted by changes in donor demographics. An "organ supply line" for organ transplantation is organ preservation. The ideal way to use a preserved organ is to use hypothermia to suppress metabolism. As a result, the adoption of such cutting-edge methods has increased the demand for organ transplants worldwide by propelling the transplantation industry forward, this factor fueling the growth of organ transplantation market.
For instance, in September 2022, according to UW Medicine, the Organ Procurement Organization for Washington, and UW Medicine’s heart transplant team together facilitated the Pacific Northwest’s first donation-after-circulatory-death (DCD) heart transplant.
In January 2022, Novartis today announced a collaboration with Alnylam to leverage Alnylam’s proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for Biomedical Research, potentially leading to the development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.
In July 2022, Zimmer Biomet Holdings, a global medical technology leader, and Hospital for Special Surgery (HSS), the world's leading academic medical center focused on musculoskeletal health, today announced a first-of-its-kind, three-year agreement to create the HSS/Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI) in Robotic Joint Replacement. Through the collaboration, ZB and HSS aim to develop new decision support tools, powered by data collection and machine learning, to provide data-driven recommendations to surgeons for robotic-assisted joint surgery.
High cost of organ transplantation : One factor driving up the cost of transplantation is the scarcity of available organs. There is frequently a shortage of organs compared to the demand, which prolongs patient waiting periods. Patients' increased healthcare costs during their transplant waiting period contribute to the overall financial burden of the longer wait times. Immunosuppressive drugs must be taken for the rest of a patient's life to prevent organ rejection after transplantation. These drugs can be very expensive, and your insurance may not always cover the whole cost. The success of transplantation outcomes may be impacted by patients' inability to adhere to prescribed regimens due to financial difficulties in obtaining a steady supply of medications. The whole cost of organ transplantation is influenced by the possibility of complications following the transplant and the requirement for ongoing follow-up care. Financial resources for patients and healthcare systems may be strained by ongoing monitoring, diagnostic procedures, and additional treatments. Population differences in terms of income can make the problems brought on by the high expense of organ transplantation worse. Lower socioeconomic status people may have trouble accessing high-quality medical care, which could result in differences in transplant success and rates, this factor hinders the growth of the organ transplantation market.
For instance, in June 2020, according to Shalby Hospitals, on average, the cost of a liver transplant in India an indicative range would be somewhere between USD 24,400 – USD 36,600.
High Rejection Rate for Transplants : The process of transplant rejection occurs when the recipient's immune system attacks the organ or tissue that has been transplanted, perceiving it as alien. Acute, chronic, and hyper-acute rejections are the three forms of rejections that are typically reported. There are situations in which organ transplants fail because the recipient's body rejects the transplant despite donor matching, tissue typing, and the use of immunosuppressants. Failure to comply with immunosuppressive medication is one of the main causes of transplant rejection. Certain cancers, infections, loss of function in transplanted tissue or organ, and severe side effects from improper medication dosages are possible complications resulting from transplant rejection.
Immunosuppressive medications and artificial organs will open up new markets for the transplantation industry : Immunosuppressive medications are essential in preventing organ rejections and are used extensively in transplant procedures. It is therefore anticipated that the segment will expand steadily. The field has experienced significant growth in recent years due to the introduction of ortho-biologics, and this trend is expected to continue shortly. Therefore, immunosuppressive medications offer profitable chances for the transplant industry to expand. In a similar vein, the market for transplants is expanding due to the availability of artificial organs. There are several varieties of artificial organs on the market. These artificial organs are divided into three categories: mechanical, biomechanical, and biological. Inanimate polymers like metals and plastic make up mechanical organs. Polymers that are inanimate and living cells combine to form biomechanical organs. Living cells comprise biological (bioartificial) organs, which decompose naturally.
|Market Size in 2022
|USD 12.92 Billion
|Market Forecast in 2030
|USD 27.25 Billion
|Compound Annual Growth Rate (CAGR)
|Revenue (USD Million) and Volume (Kilo Tons)
|By Product, By Application, By End-Use & By Region
|2018 - 2022
|2023 - 2030
Segment Analysis of the Organ Transplantation Market
The organ Transplantation Market is segmented by product, application, end-use, and region.
The Tissue Products segment held the largest market share in 2022 : The product is sub-segmented into tissue products, immunosuppressive drugs, and preservation solutions. The Tissue Products segment accounted for the highest market share 57.70% in the global organ transplantation market for 2022. Tissue products, immunosuppressants, and preservation solutions are the main products used in organ or tissue transplantation. The segment's growth is ascribed to the rising number of transplant procedures, including those involving cochlear implants, heart valves, bone marrow, and orthopedic soft tissues. Furthermore, the development of new products is driving market expansion. To increase the scope of their current product line and solidify their place in the market, manufacturers are concentrating on joint ventures, mergers and acquisitions, and the development of new products. For example, Stryker Corporation announced that it had acquired Instratek, a top producer of instruments for minimally invasive soft tissue recession for procedures involving the ankle, foot, and upper extremities.
On the other hand, the immunosuppressive drugs segment has a significant market share over the forecast period, due to immunosuppressive medications are essential to organ transplant success. They prevent the transplanted organ from being attacked by the recipient's immune system because they suppress it. Without these medications, transplant rejection would happen and the process would be pointless.
A variety of organ transplants, such as kidney, liver, heart, lung, and pancreas transplants, require the use of immunosuppressive medications. Their large market share is a result of their extensive use in a variety of transplant types.
The kidney segment was the leading segment in 2022 : By Application, which is divided into heart, kidney, liver, and others. the organ transplantation segment accounted for the largest share 47% in the global organ transplantation market in 2022. Kidney failure is a common illness that affects millions of people globally. The main cause of kidney failure, chronic kidney disease (CKD), is thought to impact 10% of the world's population. Kidney transplants have a comparatively higher success rate and longer graft survival than other organ transplants. This is because donor organ matching, immunosuppressive drugs, and transplant procedures have advanced. Patients with end-stage kidney failure have a much better quality of life after receiving a kidney transplant. Patients can resume their daily activities, are no longer subject to dietary restrictions, and are independent. The need for kidney transplants is further supported by this enhanced quality of life. Kidney transplants are anticipated to continue to be the most common organ transplant procedure due to these reasons.
The liver segment is anticipated to register rapid growth in the forecast period, Hepatitis B, hepatitis C, and cirrhosis are among the many liver diseases that millions of people worldwide suffer from. The only effective treatment for end-stage liver disease, which is defined by severe liver damage and the inability to carry out vital functions, is frequently liver transplantation. Liver transplant success rates and long-term results have skyrocketed due to advances in immunosuppressive drugs, postoperative care, and transplant techniques. As a result, more people need liver transplants, which can save their lives for those with end-stage liver disease. Patients in need now have greater access to liver transplants due to the rise in transplant centers offering this procedure worldwide. The liver transplant market has grown as a result of the transplant centers' expansion.
The hospital segment was the leading segment in 2022 : By End-Use, which is divided into hospitals, transplant centers, and others. the organ transplantation segment accounted for the largest share of the global organ transplantation market in 2022. Hospitals are equipped to perform intricate organ transplant procedures because they have specialized surgical suites, cutting-edge medical equipment, and skilled staff. To guarantee continuity of patient care, they also offer pre- and post-transplant care. Physicians with specific training in organ transplantation, such as intensivists and transplant surgeons, are primarily found in hospitals. For transplant outcomes to be successful, this knowledge is essential. Organ procurement organizations (OPOs) that facilitate the distribution of donor organs are frequently associated with hospitals. Because of its proximity to the organ supply chain, hospitals are guaranteed prompt access to organs for transplant procedures. Hospitals offer integrated care, which includes all transplant services from matching donors and pre-transplant evaluation to long-term care and follow-up after the transplant. Patient care is streamlined and results are enhanced by this integrated approach.
The transplant centers segment is anticipated to register rapid growth in the forecast period, growing numbers of transplant centers are required to meet patients' unmet needs as a result of the growing complexity of these procedures. Additionally, growing government campaigns to promote organ donation are anticipated to fuel market expansion. For example, the Division of Transplantation of the Health Resources and Services Administration funded four grant programs aimed at raising the number of organ donors and transplant procedures. The need for cutting-edge transplant products for the treatment of organ failure and tissue replacement has grown as a result of the developed healthcare infrastructure in the United States, France, the United Kingdom, and other European nations. Furthermore, these areas are becoming home to an increasing number of cutting-edge transplant centers.
North America occupied the largest market share in 2022 : North America has the largest revenue market share 42% in 2022, The region's well-developed healthcare system, the population's growing expenditure on personal health, and the ongoing development of novel transplantation products for treatment are the factors propelling the market's revenue growth. Additionally, the robust presence of numerous sizable biotechnology and medical device companies is anticipated to propel the market's revenue expansion in North America. Additionally, the US and Canada's supportive government policies are fostering the revenue expansion of this market. In the US, 118,020 people needed organ transplants in 2017, according to the Organ Procurement and Transplantation Network. Organ failure rates have surged along with the prevalence of chronic illnesses like cancer, kidney diseases, and heart problems.
On the other hand, Asia Pacific accounted for a significant share over the forecast period, with more than 4.7 billion people, the Asia Pacific region is home to the world's largest population. The demand for organ transplants is high due in part to this large and expanding population base. In the Asia Pacific area, the prevalence of chronic illnesses like diabetes, heart disease, and liver disease is rising quickly. The need for organ transplants is fueled by these illnesses, which are the primary causes of organ failure. There is a higher supply of donor organs because organ donation rates have been rising in many Asia Pacific nations. The market for organ transplants is expanding as a result of the increased availability of donors. The Asia Pacific region is seeing an increase in both the number of transplant centers and the availability of highly qualified transplant surgeons.
List of the prominent players in the Organ Transplantation Market:
- Novartis AG
- Pfizer Inc.
- Terumo Corporation
- Preservation Solutions, Inc.
- Trans Medics, Inc.
- Organ Recovery System
- AbbVie Inc.
- Zimmer Biomet
- 21st Century Medicine
- BioLife Solutions.
- Teva Pharmaceutical Industries Ltd.
- Veloxis Pharmaceuticals Inc
- Redhill Biopharma Ltd.
- Organ donor
- NHS Blood
Segmentation Analysis of the Organ Transplantation Market
- Tissue Products
- Immunosuppressive Drugs
- Preservation Solution
- Transplant Centers
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Impact of the COVID-19 Pandemic on the Organ Transplantation Market:
The global healthcare system is in a state of chaos as a result of the coronavirus's explosive outbreak at the beginning of 2019. In hospitals and ambulatory care facilities, governing bodies have been forced to postpone elective and non-urgent surgery due to the large number of coronavirus patients admitted to public and private institutions. Global registrations for organ transplant surgery decreased as a result of the pandemic. The lack of resources, skilled surgeons, lockdown, and travel restrictions are the main causes of the decline in organ donation and transplantation procedures. Organ donation is discouraged for patients with positive COVID-19 test results because of the risk of infection. Furthermore, one of the main variables influencing the transplantation processes is the potential for immunosuppressant medications to interact with COVID-19 treatment medications. It has also led to a large number of transplant donors rejecting their organs. The global market was impacted by the COVID-19 outbreak because there was a decrease in trauma and injury incidents worldwide. The decreased patient visits to medical professionals as a result of the coronavirus further exacerbated the COVID-19 pandemic in 2020. For example, according to data from the U.S. Department of Health and Human Services (HHS), in 2021 the COVID-19 pandemic had a major effect on the number of organ transplant procedures performed in the United States; in 2020, there were 39,036 procedures performed in the United States, compared to 39,719 in 2019, a 1.7% decrease. This meant that the decrease in patient visits hurt multiple procedures.